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Dr. Turan as systematically optimized the preparation of POLII-bound DNA (chip DNA) using anti-POLII antibodies and provided these to Dr. Raymatpanah. In addition Dr. Rahmatpanah has used this optimized protocol to prepare additional DNA. For example, MDA453 human breast cancer cells with high levels of HER2, have been compared to MCF7 human breast cancer cells which do not express HER2 using Agilent arrays. Examples of the hybridized arrays are shown in the appendix, Figures 1 and 2 . These arrays are nearly free of background and exhibit excellent signal to noise ratios indicating that suburb data has been obtained. The data has been collected and analyzed. This preliminary analysis reveals numerous genes significantly bound by POLII in the high HER2-expressing cells. Examples are listed in the Appendix, Table 1 . The HER2 pathway is associated with activation of the EGF receptor signal transduction intermediates such as ErkI/II and , Elk-1. Our preliminary include a number a number of novel genes important in growth, angiogenesis, and in particular Wnt signaling. It has long been known that activation of Wnt ligand genes is important in one mechanism of breast cancer tumor genesis. Our results suggest a possible linkage of HER2 signal transduction pathway to activation of the Wnt pathway. Here it should be emphasized monotherapy of human breast cancer using Herceptin alone has only provided margin increased in survival, about 3-5 months. Thus, it is suspected that there exist HER2 dependent activity that is not blocked by inhibition of HER2 by Herceptin. Our preliminary analysis suggests potential additional HER2-related targets.
We are extending our analysis to the comparison of other sets of high and low HER2-expressing cells including MC7cells with constitutive expression of HER2 compared to control MCF7 cells. Further we are treating cells with Herceptin. This analysis will reveal what genes remain bound by POLII in Herceptininhibited cells. We hypothesize that these genes can be identified using our new MCF7 cell system by comparing genes activated in MCF7HER2 cells compared to MCF7 control cells that are not effected by the addition of Herceptin. This is potentially fundamental new information that may provide crucial new targets for combination therapy. Such gene targets may have great advantages over the use of nonselective and toxic compounds such as the platinum compounds currently used to obtain "synergistic" responses in therapy.
We have confirmed that Herceptin impedes the reported activities of HER2. We are now hybridizing DNA from cells treated with Herceptin for comparison to the results for untreated cells. Next, the results described here will be duplicated in order to provide data sets for extensive statistical analysis. In summary, after considerable systematic optimization of protocols, excellent data is now being generated from defined cell systems which strongly indicates that our analysis can be completed. Dr. Rahmatpanah has submitted an abstract for the 100 th annual AACR meeting which has been accepted and will be presented in April.
II. Progress 9/2009 -5/2010.
The final 9 months period of this project have focused on bioinformatics analyses of the accumulated data in order to identify HER2-regulated genes, the subsets of HER2-regulated genes that exhibit significant expression, and the analysis of unifying biochemical pathways in accordance to the major goal of this grant..
Determination of HER2-dependent gene expression in breast cancer cell lines and tumors.
We performed whole genome expression analysis on a series of cell lines using U133plus2 arrays with ~54,000 probe sets. We studied MCF7 breast cancer (BCa) cells that in their natural state do not express HER2, and constructed a line, MCF7HER2, that expresses large amounts of active HER2 (Figure 11) . We compared these results with expression data from breast cancer cell lines with naturally amplified HER2: BT474 and MDA453. We also compared expression profiles in these cell lines with the measured values for existing profiles of HER2+/-primary breast tumors, totaling 812 primary breast cancer cases in five data sets 1 ( Table 2) . For this 5 latter comparison the top 35% of tissues with the highest HER2-expression were taken as HER2 + and the bottom 35% of tissues with the least HER2 expression were taken as HER2 -. Statistically significant (p < 0.05) differentially expressed genes in each HER2 expressing cell line vs. the non HER2 expressing cell line (top 3350, all p < 0.05) were compared to the most significant 3350 (all p < 0.05) genes from primary tissue datasets. The overlapping genes between each cell line and the primary tissues were overwhelmingly regulated in the same direction in cell lines and in breast cancer tissues; MCF7HER2, 273/459 (60%); BT474, 335/502 (67%); and MDA453, 349/502 (70%) respectively. Agreement analyses for these comparisons were all significant (Kappa statistics, p < 0.0001) (Figure 12 , Table 3 ). The same comparisons were performed on randomly selected genes and kappa values were calculated for 1000 rounds.
The kappa values averaged ~0.05, near random expectation.
Determination of HER2-dependent Genes poised for transcription. Although primary tumors and the three cell lines exhibit overall similar regulation of HER2-dependent genes, about 30% of HER2-correlated genes are regulated in a different direction in the primary tumors vs. cell lines. In addition, the majority of genes showing expression correlation with HER2 were unique to particular cell lines or to primary tumors. Therefore, we examined the hypothesis that there are a group of genes in HER2 expressing cell lines that are ready to be expressed but are not expressed. Such non-expression could be due to a lack of signals that would occur in the tumor environment in the patient 2 . For this test, we compared transcription profiles of HER2+/-cell lines to the distribution of RNA Polymerase II (POL II) bound to promoters and the adjacent exons. RNA Polymerase II (POL II) was chosen as a probe for HER2-directed gene regulation because HER2 is not a transcription factor and there is, as yet, no well-defined small number of transcription factors known that mediate gene regulation of the pathways regulated by HER2.
Many details of the mechanism of transcription by POL II are now known through studies of Drosophila melanogaster, yeast and E. coli 3, 4 . Of the three well-recognized RNA polymerases, POL II is the major nonnucleolar polymerase of transcription. Promoter binding occurs in the region of the transcriptional start site (TSS) of protein coding and ncRNA genes, in association with a large complex of initiation factors to form the promoter initiation complex (PIC). POL II may remain poised or stalled in this state. The initiation of transcription involves further association with specific transcription factors and TATA-binding factors, chromatin modification and phosphorylation of the C-terminus of the largest of the 12 POL II subunits. For example elongation is associated with gain of phosphorylation at ser5 and chromatin modifications leading to H3K79me2. A number of variations in regulation are known such as the association of promoter-bound POL II with distant 5' enhancer elements by DNA looping. POL II may be engaged in limited motion leading to short ~35 nt transcripts or "abortive" transcription and "divergent" transcription along the antisense strand. Within coding sequences where transcript elongation is occurring, further pausing is commonly detected in one or more 3' sites. It has been shown that POL II is stalled upstream of important transcriptional factors such as c-Myc in both yeast and human embryo stem cells (ESCs), indicating that some POL II locations might constitute nuclear hallmarks important for cell growth and development 5 . Genes poised for transcription (POLII bound) in a model of HER2 overexpression. Pathway analysis of genes with POL II binding sites in MCF7HER2 (606 genes) using Database for Annotation, Visualization and Integrated Discovery (DAVID) {Jiao, #62} bioinformatics produced a list of five highly significant gene ontology (GO) terms (Benjamini score 8.20E-07 to 9.5E-04 ) focused in five main functions, homeobox, developmental, kinase, tyrosine protein kinase and phosphotransferase.
Our data identified more than 30 homeobox genes that gained POL II binding sites in HER2 expressing breast cancer cell line (e.g., MCF7HER2), but not the control MCF7 cells with no HER2 expression. Among POL II bound homeobox genes is HOXB7 which has been reported to promote tumor progression, survival and metastasis once tumorigenesis has begun in HER2 overexpressing breast cancer 6 . It has been shown that POL 6 II stalls at the promoter region of HOXC6 and HOXC8 in mouse embryonic stem cell 7 . Moreover, many of the identified POL II bound homeobox genes here have been shown to be associated with three transcriptional factors NANOG, OCT3/4 and SOX2 in both normal and tumors cells 8 . These transcription factors and their associated genes have the capacity to control the self-renewal and pluripotency of embryonic stem cells. A recent study conducted by Hee Noh, et al. has shown that NANOG activates AKT signaling via T cell leukemia /protein 1a (Tol 1A) which, in turn, promotes a stem cell-like phenotype and immune evasion in cancer cells 9 . There are numerous reports of association between activated AKT signaling pathway and HER2 overexpression in breast cancer 10 . However, the association between NANOG/AKT and HER2 over expression in breast neoplasia has yet to be fully investigated.
As a control we applied the same functional analysis procedures to the 678 unique genes that were found to bind POL II in MCF7 cells which do not express HER2. The analysis revealed a strikingly different set of functions such as for glycoproteins, transport proteins, cell adhesion proteins, phosphoproteins, and voltage gated channels. Moreover the fit of the 678 genes to these functional groups exhibited markedly higher probabilities, 5 x 10 -3 -10 -2 vs. 10 -3 -10 -7 . These observations argue that the genes identified for HER2-expressing cells are specific HER2-dependent POL II binding genes.
Genes poised for transcription (POL II bound) in human breast cancer cell lines with acquired amplification of HER2. As noted in part I of this report, we extended the ChIP-chip analysis to two human BCa cell lines that exhibit marked amplification of HER2 and very high HER2 protein levels (e.g., Figure 11 ), BT474 cells and MDA453 cells (Table 11) . 266 and 285 of the 606 (POL II bound genes in MCF7HER2 cell line) genes were detected as significantly bound (p < 0.05) in MDA453 and BT474 respectively. The overlap among these two groups of genes that bound POL II among the three cell lines is significant (p < 0.008) when compared to simulation studies of randomly selected genes from both lines with amplified HER2. The observations indicate the reproducibility of the results based on the MCF7HER2-MCF7pcDNA model and indicate that the model system is relevant to the effects of amplified HER2 in breast cancer.
We quantified the amount and location of POL II binding in each promoter region using previously defined POL II stalling index with slight modification 4 . POL II stalling index was determined for all three high HER2 expressers (MCF7HER2, BT474 and MDA453) in compared to control cells (MCF7pcDNA). Our results illustrate a large effect of HER2 overexpression in shifting the POL II binding site toward the downstream of the TSS as indicated by stalling index (Figure 13) .
When compared POL II binding with gene expression most genes had no POL II binding and tended to be among the genes that were not transcribed. Among the HER2-correlated binding events, some genes had strong POL II binding in their promoters (Figure 13 ) and these genes also tended to be among those that were not transcribed. These promoters are presumably where transcription is poised to occur but is not active 4 . Finally, there were genes that had weak or intermediate binding of POL II; this latter class was more often associated with statistically significant differentially expressed genes (Figure 14) .
A group of "relevant" genes (a total of 737) were defined as those with detectable POL II binding (both tight and loose binders with p < 0.05 and 0.05 < p < 0.13, respectively ( Table 4 , Figure 15 ), explained in Supplementary Material and Methods, both in the promoter region and downstream of the transcriptional start sites (TSS) in all three cell types that expressed high levels of HER2 (MCF7 HER2, as well as in the naturally high expressing BT474 and MDA453 cell lines), but not in the MCF7 controls that do not express HER2 (Figure 15 ). These genes are termed the HER2 Regulon here. 93 of these genes were transcriptionally regulated (all with p < 0.05) in HER2 expressing breast cancer cell lines when compared to those cells that do not express HER2. 51 of these genes were regulated in the same direction in all three cell lines with high HER2 expression. Of such genes, 36 were down regulated and 15 up regulated.
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Moreover, 36 additional genes of the 93 genes were found to be regulated in the same direction in two of the three cell line comparisons ( Table 5) .
Next we asked whether those gene transcripts that are regulated in the same direction (51 genes) in HER2
+ versus HER2 -cell lines are in concordance with the expression levels in HER2 + versus HER2 -tissues based on the analysis of the 812 primary tissue datasets. 28 of the 51 genes were assayed among the five external tumor tissue datasets (812 cases). 13 of these 28 genes are significantly differentially expressed in the primary tumor datasets (all with p < 0.05) and 10 of the 13 genes are transcriptionally regulated in the same direction in both high HER2 cell lines and the primary tissues (Kappa value, 0.54 and p < 0.02) ( Table 5) .
Up and down-regulated transcripts in high HER2 expressing cell lines from POLII bound genes Among down-regulated genes are; MRAS, SOCS5, GAB2, STMN3, PPP3CC. Five genes (SEMA3F, BLVRB, PTPRF, MARCKS, and CQQ6) are up regulated both in HER2 positive cell lines and in high HER2 expressing primary breast tumor tissues ( Table 5) . Among the discrepant genes between cell lines and primary breast tumors; one gene (CDKN2D, cyclin dependent inhibitor 2D, inhibits CDK4) is up regulated in three high HER2 expressing breast cancer cell lines and down regulated in HER2 + expressing breast carcinomas whereas, two other genes (CNOT2, PAPSS2) are down regulated in HER2 expressing cell lines and up regulated in HER2 overexpressing breast cancer tissues. CNOT2 (CCR4 associated factor 2) regulates mRNA synthesis through interaction with HDAC1 and is a regulator of stem cell maintenance 11 . This gene binds to and inhibits TFIID which binds to the core promoter to position POL II properly and acts as a channel for regulatory signals. 23 of the 51 genes that are regulated in the cell lines in an HER2 dependent manner were not assayed in the combined external breast tumor tissue datasets however, all are transcriptionally regulated in the same direction among all three high HER2 expressing cancer cell lines (p < 0.05) ( Table 5) . Several of these genes are described in breast cancer including FN1, Fibronectin1, which is down-regulated in high HER2 expressing cell lines, and has been reported to be suppressed in metastatic breast cancer 12 .
POL II bound genes in high HER2 expressing cell lines that are not transcribed. Our data revealed the identity of 737 genes with POL II binding sites in HER2 + cells. 686 of such genes are not transcriptionally regulated in the same direction in all three HER2+/-comparisons ( Figure 15 ). These are POL II bound genes "poised" in HER2 expressing cell lines without transcripts that are differentially regulated in HER2 dependent manner. We compared the expression levels of 686 POL II bound genes with no significant differential expression in all HER2+/-cell lines to the 3350 significantly HER2 dependent differentially expressed genes in five primary tissue data sets totaling of 812 cases. 113 genes were significantly differentially expressed in HER2 + primary tissues compared to HER2 -primary tissues ( 23 . Several of these genes have been reported previously to be associated with high levels of HER2 expression in human breast and ovarian neoplasia ( Table  6) .
Pathway analysis of genes poised for transcription in cell lines and differentially transcribed in breast cancer. Functional relationships of the 113 differentially expressed genes were examined by computer-assisted searches using MetaCore software and Strand -NGS pathway analysis tools (Agilent) .Two main processes were overrepresented in this subclass of HER2 regulated genes including inflammation, immune response especially for interleukin 5, 9, 4, 1,13 and developmental pathways such as, Hedgehog, Notch and Wnt. Previous studies using gene expression analysis of different breast cancer cell types have indicated that inflammation within the tumor microenvironment (cellular context) of breast tumors may enhance tumor progression through increasing motility and invasion 24 . The reciprocal interactions between tumor and stromal 26 . Among signal transduction pathways associated with HER2 regulated "poised" class of 113 tissue dependent genes were insulin, androgen receptor signaling cross talk, Hedgehog, Notch and Wnt signaling. These findings are consistent with published data that implicates the cross-talk among HER2, Notch, Hedgehog and Wnt pathways in HER2 positive breast cancers 27 . High HER2 expressing tumor cells display activated Notch signaling [45] . Both HER2 and Notch signaling play roles in regulating cancer stem cell 27 . Additionally, many of the 113 HER2 regulated genes were associated with stem cell and progenitor cell control, as indicated by networks centered on NANOG (FBXO2, CLIC4, PTCH1, RIF1, VRK2, BRD2, Presenilin 2, RAP-1A, Sequestosome 1(p62), OCT3/4 (ATP5G1, BAIP3, BRD2, CtBP2, NUMA1, PGAP1, PTCH1, RBBP7(RbAp46), RIF1, WHSC1) and SOX2 (CtBP2, CLIC4,DKK1) (Figure 3) . Previous studies have demonstrated that core transcription factors, such as NANOG, SOX2 and, OCT3/4 are involved in the maintenance of pluripotency and self-renewal in embryonic stem cells (ESCs), and have been identified in tumors of various origins (reviewed in 6 ). Indeed, we have confirmed significantly increased expression of NANOG, SOX2 and, OCT3/4 in cultures of "mammospheres" of MCF7HER2 cells compared to attached cultures and to MCF7pcDNA3 cells (Figure 7) . Thus, a role for stem cells in proliferation of HER2-regulated breast cancer is highly suggested.
38 of the 113 genes were associated with CREB1 (cAMP responsive elements binding protein) which regulate aromatase in breast cancer. It has been reported that over-expression of aromatase in adipose tissue surrounding breast tumor (microenvironment) could arise through increase in both CREB expression and CREB transcriptional activity 28 ( Figure 16 ). Moreover, expression of CREB1 has been reported to be associated with poor prognosis and metastatic breast cancer 29 . In all the four node genes, NANOG, SOX2, OCT3/4, and CREB1, are associated with the regulation of 57 of the 113 genes (Figure 16 ). The gene regulation changes that are tissue context-dependent represent a fundamental new class for understanding HER2 mechanisms in breast cancer.
487 more genes with POL II binding in HER2 positive cell lines were identified. This class of genes has no transcripts that were differentially expressed in HER2 + / -breast cancer cell lines. These genes were not assayed in the five combined breast cancer tissue datasets (i.e. 3350 significant genes in the merged primary data). A literature search using the MetaCore pathway analysis tool revealed an association of 124 of these 487 genes with breast neoplasia. The remaining genes have no previously documented association./
KEY RESEARCH ACCOMPLISHMENTS:
Bulleted list of key research accomplishments emanating from this research.
 Extend cell system for the analysis of genes activated by HER2. In addition to using the original panel of BT474, MDA-MB-436; MDA-MB-453; and MDA-MB-468. MDA-MB-463, the MCF7 based system with constitutive expression of HER2 (Frank Jones, UCCHS) has been obtained and is in regular use.  Obtained Herceptin humanized monoclonal antibody for the inhibition of HER2.Established an optimized protocol for preparing POLII-bound DNA from living cells. Established western analysis protocol for the characterization of anti-POLII chromatin immunoprecitated DNA.  Established optimized protocols for the hybridization of POLII precipitated DNA to our promoter arrays with 15,000 promoter sequences and Agilent oligonucleotide arrays.
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 Using our scanned hybridized array data, we have carried out preliminary analyses of hybridization data showing excellent signal to noise characteristics and have identified genes significantly bound by POLII using our webarray and Agilent software packages ( Table 1) .  Identified HER2-dependent poised and expressed genes in human breast cancer cell lines.  Discovered that a set of 113 HER2-dependent expressed genes require the tumor context or anchorage independent context.  Discovered that most of the 113 Her2-dependent genes have regulatory relationships with the 4 pluripotency genes NANOG, SOX2, OCT3/4, and CREB1 indicating that HER2 may induce cancer stem cell formation via induction of NANOG, SOX2, OCT3/4, and CREB1.
PUBLICATIONS, ABSTRACTS, PRESENTATIONS.
Rahmatpanah 
INVENTIONS, PATENTS, LICENCES. (Nothing to Report)
Pending support. (Nothing to report).
CONCLUSION.
Summarize the results to include the importance and/or implications of the completed research and when necessary, recommend changes on future work to better address the problem. A "so what section" which evaluates the knowledge as a scientific or medical product shall also be included in the conclusion of the report.
HER2-positive breast cancer accounts for 25% of all cases and has a poor prognosis. Although progress has been made in understanding signal transduction, little is known of how HER2 achieves gene regulation. We performed whole genome expression analysis on a HER2 + and HER2 -breast cancer cell lines and compared these results to expression in 812 primary tumors stratified by their HER2 expression level. Chip-on-chip with anti-RNA polymerase II was compared among breast cancer cell lines to identify genes that are potentially activated by HER2. The expression levels of these HER2-dependent POL II binding genes were determined for the 812 HER2+/-breast cancer tissues. Genes differentially expressed between HER2+/-cell lines were generally regulated in the same direction as in breast cancer tissues. We identified genes that had POLII binding in HER2 + cell lines, but without significant gene expression. Of 737 such genes "poised" for expression in cell lines, 113 genes were significantly differentially expressed in breast tumors in a HER2-dependent manner. Pathway analysis of these 113 genes revealed that a large group of genes were associated with stem cell and progenitor cell control as indicated by networks centered on NANOG, SOX2, OCT3/4. HER2 directs POL II binding to a large number of genes in breast cancer cells. A "poised" class of genes in HER2 + cell lines with POLII binding and low RNA expression but is differentially expressed in primary tumors, strongly suggests a role of the microenvironment and further suggests a role for stem cells proliferation in HER2-regulated breast cancer tissue. of Herceptin is being developed as an improvement of the identification of gene targets of cisplatin.
REPORTABLE OUTCOMES.
Dr. R. An example of hydrization of DNA of human breast cancer cells with amplified HER2 hybridized in competition with genomic DNA to commercial Agilent oligonucleotide arrays. These arrays provide prmoter binding information for over 17,000 human genes compared to 10,525 of our fabricated arrays. We are proceeding with our analysis with both platforms as the overlapping genes will provide a stringent measure of reproducibility. The total number of POL II bound genes in high HER2 expressing cells was compared to those of nonexpressing HER2 cells (e.g., MCF7pcDNA). The number of uniquely bound POL II genes as well as the number of common genes for each pairwise comparison is shown. Tightly bound POL II genes is indicated as p < 0.05, whereas 0.05 < p < 0.13 indicates number of loosely bound POL II genes. Comparison of the distribution of binding of POL II in MCF7HER2 cells to control cells revealed a striking patterns of rearrangement associated with the expression of HER2 consisting of binding to new genes of the HER2-expressing cells and loss of binding to previously bound genes of the control cells. For example, 678 POL IIbinding genes in MCF7pcDNA control cells no longer bound POL II in MCF7HER2 cells. In contrast in HER2-expressing cells exhibited 606 other genes that gained POL II binding indicating a very substantial shift in the localization of POL II upon the stable expression of HER2. In addition changes in the number of sites bound per gene for genes common to the two cell types were also identified. 
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Recent studies revealed that Herceptin (Trastuzumab), a humanized monoclonal antibody to the cell surface growth factor receptor HER2 (Erb2), is a break-through in treatment for HER2 positive, advanced breast cancer. HER2 is over-expressed in 25 to 30% of all primary breast and ovarian cancers, and is associated with poor clinical outcome in the vast majority of these cases. Treatment of HER2 positive cancers with Herceptin promotes down regulation of HER2 thereby blocking signaling from the HER2 growth factor receptor and causes cytostatic growth inhibition. However the clinical trials, involved women with high levels of HER2, revealed that Herceptin as a mono therapy was effective in only 12% of these patients, which implies that this agent might be effective in subsets of breast tumors with high levels of HER2. In fact as a mono therapy in clinical trials the survival rate by Herceptin alone is at best modest (only three months gain in survival).While promising, this gain is short on the scale of normal remaining life expectancy. Indeed in aggressive type of breast cancer, neither the underlying mechanisms by which HER2 over expression/amplification promote breast cancer progression, nor the inhibitory and resistance to Herceptin are fully elucidated. The question that remains unanswered is whether there may be a Herceptin target(s) that is not inactivated by the binding of the Herceptin antibody to the extracellular domain of HER2. This may include the ability of HER2 to dimerize with other members of the EGFR family. In addition, an important mechanism that may underlie the action of HER2 is based on the identification of an alternative spliced variant of HER2 which is associated with aggressive breast cancer. This alternate spliced product may not be inactivated by Herceptin. Thus, additional strategies that inhibit alternatives mechanisms of HER2 may constitute crucial agents for treatment. In order to define targets of HER2 signal transduction that are not inhibited by Herceptin, we are testing whether HER2 promotes gene activation that is not blocked by Herceptin. Therefore, we aimed to identify the crucial downstream targets of HER2 and key genes that are not altered by the combining of Herceptin with HER2 using genome wide location analysis (Chip-on chip).We examined the differences between the enrichment of RNA Pol II in promoter regions of three cell lines that were known to be high expressers of HER2 (SKBR3, BT474,MDA453) and low HER2 expressing cell lines (MCF7,MDA231, MDA468) before and after treatment with Herceptin. We used microarray platform that were generated in our laboratory "promoter array" in combination with Agilent promoter array. Our results demonstrated that RNA Pol II is bound to a larger # of genes in breast cancer cell lines expressing high levels of HER2 than those expressing low levels of HER2. 
INTRODUCTION
Knowledge of the genome sequence and the regions of functional promoter sequences have made it possible to identify cohorts of genes that are coordinately regulated during normal cell responses or as part of a disease process. The first step is the fabrication of arrays of known promoter sequences. These arrays can be used to identify the genes corresponding to regulatory sequences that have been isolated from biologically relevant experiments by, for example, chromatin immunoprecipitation (ChIP) or by using a differential digestion strategies.1,2 In the case of yeast, most of the regulatory sequences occur in the intergeneic regions and arrays containing these sequences provide the identity of any yeast regulatory sequence.3 In the cases of mammalian cells where the vast majority of noncoding DNA may not be related to regulatory functions, the construction of mammalian promoter arrays had to be restricted to regions where annotation of regulatory function is available. Advances in technology will likely make pangenomic surveying of nearly all regulatory regions of the mammalian genome possible in the near future. Here we review recent experience using a prototype array containing 3083 unique sequences of 1 to 1.5 kB from regions of proximal promoter sequences. The sequences chosen are particularly suitable for the analysis of AP-1 regulated genes and regulation dependent on GCrich sequences such as those utilized by the Sp1 and Egr1 transcription factor family or regulation by methylation.1,2,4 The array has been applied to study gene regulation of human breast and prostate cancer cells. We have used a "chIP-on-chip" strategy to examine the regulation of genes of breast cancer cells following genotoxic stress. In addition the arrays have been used to identify genes regulated by methylation or change of copy number in human prostate cancer cells. Although sampling a very limited portion of the genome, the results indicate a versatile method and further indicate a surprisingly large scale nature of gene regulation by diverse mechanisms. "Chromatin immunoprecipitation" or ChIP refers to methods for the isolation of chromatin specifically bound by a protein of interest by immunoprecipitation using an antibody to that protein. The method utilizes a simple cross-linking step to covalently stabilize DNA-protein complexes which are usually carried out as the first step by briefly treating cells with formaldehyde. The potentially unwieldy mass of crosslinked chromatin created by such a procedure is obviated by treatment of the crosslinked chromatin with restriction enzymes or by sonication, which rapidly produces a relatively uniform population of fragments of protein-DNA complexes that are readily precipitated by conventional immunoprecipitation. For such a relatively simple method, the potential yield of exciting new information about gene regulation is impressive. First, the crosslinking step may be applied directly to living cells and so physically "captures" the proteins interacting with DNA at the site and in the context of the functioning living cell. The information is more direct than by prior ap proaches such gel shift assays or even DNAase I mapping methods which require cell disruption. Second, potentially all DNA sites bound by a protein of interest are isolated providing the opportunity for pangenomic analysis. Third, the isolated crosslinked chromatin may be treated to remove either protein or DNA, thereby providing material for analysis of DNA such as identification of the genes of the bound regulatory sequences or analysis of protein such as the determination of activating modifications or determination of co-precipitated proteins. The purified DNA may be used for library preparation and cloning. Perhaps the most informative use is hybridization to arrays of known promoter sequences, "promoter arrays" in order to identify the gene origin of ChIP-captured sequences. The known identity of sites of hybridization on such arrays determines the identity of the gene from which the ChIP-captured DNA was derived. In the case of precipitation of a regulatory protein, this is the identification of all genes whose regulatory sequences were interacting with the factor under the conditions of the living cells at the time of crosslinking. Formaldehyde-mediated DNA-protein crosslinking was first used by Solomon and Varshavsky5 as a probe for in vivo chromatin structure. The method was adapted for the isolation and determination of numerous individual sequences of the SATB1 Mammalian promoter arrays that sample small portions of the human genome have been developed by several workers (e.g., refs. 11-14) and well as in our lab.1,2,4 Moreover, proximal promoter regions are commonly rich in GC-islands, common sites of gene silencing by methylation, and so promoter arrays may be used to identify sites of methylation.2,13
Oligonucleotide array technology is rapidly approaching the point where it will be possible to sample the genome at densities approximately every 103 bases (NimbleGen Systems, Inc.) thereby providing the possibility of identifying the vast majority of ChIP-captured sequences. Until that time, array construction must focus on systems of interest. We have developed arrays that contain proximal promoter sequences of most known or suspected AP-1 binding sites or that have GC-rich elements commonly utilized by the Sp1-and Egr1-family of transcription factors as well as many proximal promoter sequences of genes implicated in prostate cancer. Moreover, these sequences are common sites of methylation. These arrays have been used to examine the role of the Jun kinase(JNK)/stress-activated protein kinase pathway and methylation in prostate cancer. The studies indicate that physiologic events are accompanied by rapid and very large scale gene-binding and regulation events involving many hundreds of genes that are under the regulation of a specific signal transduction pathway.
GENE REGULATION BY THE JNK PATHWAY: ANALYSIS OF GENOTOXIC STRESS JNK in DNA Repair
JNK phosphorylates and activates the transcriptional activities of c-Jun, ATF2, and other transcription factors in response to variety of stresses including DNA damage. [15] [16] [17] [18] Genotoxic stress leads to the activation of JNK and this activation has been shown to participate in various responses in different cell systems such as such as apoptosis, cell cycle regulation, enhanced cell survival, and enhanced DNA repair. [19] [20] [21] The pathway of activation of JNK following genotoxic stress is not known precisely, but likely involves recognition of DNA damage by a large complexes containing the ATM and ATR kinases which are activated and required for activation of JNK.22-24 JNK in turn acts on a group of transcription factor substrates such as cJun, ATF2, Elk-1 and others by phosphorylation of N-terminal serine and threonine residues (FIG. 1) . C-Jun and homologs of the c-Jun family of transcription factors, JunB and JunD, interact with DNA as heterodimers with members of the c-Fos family of transcriptions. c-Jun also interacts with DNA as a homodimer or as a heterodimer with ATF2. Phosphorylation of c-Jun at serine residues 63 and 73 or phosphorylation of ATF2 and threonine residues 69 and 71 greatly enhances the transactivation potential of these factors,25-27 thereby leading to altered gene expression. We have shown that JNK leads to increased DNA repair of cisplatin-damaged DNA in several human tumor cell lines and that specific inhibition of JNK sensitizes cells to cell killing by cisplatin.19
Arrays for Identification of JNK-Regulated Genes
Our hypothesis is that this response utilizes the induction of a specific and coordinately expressed cohort of genes which includes genes of DNA damage recognition and repair.1,28 To test this hypothesis, we have explored the use of ChIP-on-chip as applied to the phosphorylated substrates of JNK. We have used antibodies specific for c-Jun phosphorylated at two of the three N-terminal activation positions, serine residues 63 and 73 and ATF2 phosphorylated at threonine residues 69 and 71. Promoter arrays were used to identify the profile of genes whose promoters formed phospho-c-Jun or phospho-ATF2 complexes. The protocol is summarized in FIGURE 2. Cisplatin is an attractive test agent since the crystal structure of the principal DNA-cisplatin adduct is well defined through crystallographic studies.29,30 Cisplatin forms intrastrand covalent links between N7 atoms of adjacent purine residues. The isomer, transplatin, is incapable of forming these crosslinks and serves as an excellent control. The cell system first examined by ChIP-on-chip was human breast cancer cells BT474.1 These cells contain amplified erbB2 gene and greatly overexpress HER2/Neu receptors and, therefore, are a model of aggressive breast cancer. Resistance to DNA-damaging agents is an important mechanism limiting therapy of this form of breast cancer.31 Indeed, treatment with cisplatin leads to rapid activation of JNK, increased phosphorylation of c-Jun and ATF2, and increased transactivation of reporter constructs within 3-6 hours. We applied ChIP-captured DNA using both antibodies for phospho-c-Jun or phospho-ATF2 to prototype promoter arrays consisting of nearly 5000 features of which 3083 are unique human proximal promoter sequences. The typical sequence used extends from 1000 to 500 about the transcription start site. We identified approximately 370 genes found in the literature from SAGE, expression analysis, and individual gene studies to be regulated by or suspected as regulated by AP-1 components (see refs. 32-37 and references therein). To determine significant array hybridization intensities, several precautions are necessary. The arrays are printed in triplicate and all experiments are carried out in duplicate and repeated with the order of dyes reversed providing 12 estimates of all intensities. This allows for accurate use of T-tests. Hybridization of the ChIP-captured DNA to the array is carried out in competition with DNA from untreated cells. The hybridization results for "negative control" sequences on the array consisting of plant, viral, and bacterial sources are subtracted from all values.
Since array hybridization intensity is assumed to be directly proportional to the amount of a particular sequence of ChIP-captured DNA, to select increases of interest, we use the criteria that all intensities should be at least 1.5the intensity of binding of DNA from control cells (fold-change 1.5) and that the T-test yield P 0.05.
Moreover, for array hybridization data of many sources it is commonly found that the standard errors are artificially low for small intensities, which enhances their apparent significance. The "B" values of Smyth38 attempts to correct for this effect and we employ the criterion of B 2.5. Using this set of three criteria applied to the data for cisplatin-treated cells just 3 h after treatment; we find that there are 269 "significant" gene-binding events (FIG. 3, cisplatin) . Very few comparable intensities are observed in transplatintreated cells and even fewer comparable intensities are observed in mock-treated cells or cells treated with cisplatin but using a control nonimmune serum. Thus the implication of these results is that DNA damage by cisplatin leads to a rapid and large-scale formation of DNA complexes with phosphorylated-c-Jun and ATF2 transcription factors. Approximately 50 of the identified genes are known or suspected AP-1 regulated genes (FIG. 3 , red gene names [color appears online only]) whereas the majority are "new" AP-1-regulated gene candidates. Since the array "samples" only 3083 sites, the projection for the entire genome is that cisplatin treatment may lead to a rapid and massive phosphorylation of c-Jun and ATF2 promoter complexes, on the order of 3300 (269 40,000/3083). It appears important, therefore, to determine that these are specific and valid estimates. The profile may be nearly entirely eliminated by prior addition of the small molecular JNK inhibitor SP600125 (FIG. 3) . Moreover, if the cells are treated with a mixture of siRNAs that have been shown to specifically eliminate the synthesis of the major isoforms of JNK, the cisplatin-stimulated profile is again eliminated (FIG. 4) . These experiments argue that the DNA damage profile is specific. To ensure that the intensities reported by the array reflect what is in the ChIP-captured DNA pool, we examined representative genes by semi-quantitative (sqPCR) and quantitative (qPCR) using primers expected to correspond to promoter sequences of the ChIP-captured DNA which supports the validity of the arrays (FIG. 5) . This pattern of results supports the conclusion that JNK specifically mediates the rapid and large-scale formation of phosphorylated promoter regulatory complexes. 
Formation of Activated ATF2/c-Jun-DNA Complexes Promotes a Net Increase in Transcription and Translation
Three observations indicate that, even though promoters contain dozens of regulatory elements, the single event of formation of phosphorylated c-Jun and ATF2 containing DNA complexes is associated with changes in transcription that are almost always in the positive direction (TABLE 1, FIG. 6) . Second, nearly all of the genes on the promoter array are also represented on the Affymetrix U133a arrays. When total RNA isolated from cisplatin treated cells is applied to an Affymetrix array, the number of significant changes in transcript level over all common genes of the two arrays is 4.6% (FIG. 6) . However, for the subset of genes reported to have increased formation of either phospho-c-Jun-DNA complexes or phospho-ATF2-DNA complexes the percent with significantly altered transcript levels by the Affymetrix criteria is a net positive 27% and 35%, respectively. Third, qPCR measurements confirmed that mRNA levels for the representative genes were elevated and maximum at or near the known time of maximum transcriptional activation following stimulation with cisplatin for all but two of the genes, RAD50 and ATM (FIG. 6 , insert graphs).1 Finally, protein expression for the same set of representative genes revealed increased protein levels following cisplatin stimulation compared to unstimulated cells which was maximal at 3 h and remained elevated for an extended period for most cases. The exceptions are again RAD50 and ATM50. Thus, among the representative genes examined there is a strict correspondence between mRNA and protein expression. The absence of increased protein for RAD50 and ATM50 may be related to large basal levels apparent for unstimulated cells which may not be elevated readily above the basal levels. The results suggest that phosphorylation of c-Jun and ATF2-DNA complexes have significant regulatory impact. phospho-c-Jun-containing complexes. This suggests the importance of DNA repair related functions especially among genes bound by phospho-ATF2.1,40
Functional Properties of Differentially Bound and Activated Genes following
The unique set of genes corresponding to multiple DNA repair-related biologic processes corresponds to a set of 24 DNA genes summarized in TABLE 3. Ten DNA repair or related genes are common to binding by phospho-ATF2 and phospho-c-Jun (TABLE 3, dark shading) suggesting gene regulation occurs by ATF2-c-Jun heterodimers. Nine genes are bound by phospho-ATF2 but not phospho-c-Jun, a result that possibly indicates that these genes are regulated by ATF2 homodimers or ATF2 and unidentified partners. The largest single group consists of 24 DNA repair-related genes. Several of these genes appear to be specifically related to the JNK as a genotoxic stress response pathway. ERCC1, ERCC2, XPA, RAD23B, MSH2, and MSH5 are among the representative sequences that were confirmed to form increased phosphorylated c-Jun and ATF2 DNA complexes upon cisplatin stimulation and also were confirmed to express increased mRNA and protein (FIG. 6) . One of these, MSH2, as well as three others, MSH6, MLH1, and PMS2, are recognized members of the NMR DNA damage recognition complex.41,42 Moreover, the roles of four other members, XPA, RAD23B, ERCC1, and ERCC3, have been shown to be participants in the repair of cisplatin-DNA adducts.43,44 Similarly, the gene products of DMC1, ATM, and UNG2 have been implicated as facilitators of cisplatin-DNA adduct repair. Thus 12 of the 24 genes have an experimental basis supporting the conclusion that they are part of a cisplatin-stimulated response pathway and/or are targets of regulation by a JNK-mediated genotoxic stress pathway. The remaining genes reported by the promoter arrays as specific targets are novel candidates as participants as response genes of genotoxic stress.
Conclusions
The array results summarized here are derived from a very limited sampling of the regulatory sequences of the genome. Indeed, only 89 known DNA repair gene promoter sequences are represented. Moreover, only c-Jun and ATF2-DNA complexes down stream of the JNK pathway have been considered. It appears likely, therefore, that many dozens of additional DNA repair-related genes may be involved in the cisplatin-induced response. The recognition of the large-scale nature of specific activation of signal transduction maybe the major lesson learned from the exploratory studies summarized here.
METHYLATION AND COPY NUMBER CHANGE DETECTION BY PROMOTER ARRAYS: ANALYSIS OF PROSTATE CANCER CELL LINES
Proximal promoter regions are common locations of so-called "CpG" islands, sites of modification of cytosine residues by methylases, an effect commonly associated with "silencing" of transcription of the associated coding sequence. Promoter arrays can be used to identify these methylated sites in cells and tissues of interest. (FIG. 7) . A methylationsensitive restriction enzyme, HpaII, was used to distinguish methylated from unmethylated DNA at all cleavage sites. For HpaII, potential cleavage sites are common and therefore closely spaced in the CpG island as well as in the promoter region. If consecutive sites are both unmethylated, they can be cleaved and primers can be ligated. When the distance between the ligated primers is short enough, the fragment can be amplified efficiently by PCR. If, on the other hand, the DNA is methylated at one of the cleavage sites, the site will not be cut and longer and poorly amplified fragments will be produced. Thus, when HpaII digested and amplified DNA is hybridized to a promoter array, the intensities reported are proportional to the number of cells with unmethylated DNA for each sequence for which significant hybridization occurs (FIG. 7) . In addition to methylation status, the method of FIGURE 1 is also sensitive to any differences in the copy number of genes that may exist between the sample, such as a tumor cell or tissue, and normal control cells or tissues.
Copy number changes may be distinguished from methylation changes by a variety of experimental methods, such as methylation specific-PCR or by treatment with 5-aza deoxycytidine as well as in silico analysis.
Differential Hybridization of HpaII Fragments
We examined a series of prostate cancer cell lines including androgen-sensitive LNCaP cells and a series of cells increasing in metastatic potential based on the PC3 tumor lines: PC3, PC3M, and PC3M-Pro4, and PC3M-LN4 as well as three immortalized cell lines derived from prostate epithelium (FIG. 8) . We observed 504 promoters that show statistically significant changes in hybridization between cancer and normal prostate cell lines. Hierarchical clustering of the hybridization patterns of these 504 promoters is displayed in FIGURE 8 (a complete list of the genes is found in Wang et al. 20052) . The clustering results show that PC3M-Pro4 and PC3M-LN4 are the most similar. Only one promoter, HAS3, appeared to be more differentially hybridized between PC3M-Pro4 and PC3M-LN4, possibly being hypermethylated in PC3M-Pro4. PC3M-Pro4 and PC3M-LN4 were clustered with PC3M, then with PC3. These four cell lines are less similar to LNCaP and normal cell lines. This is consistent with the origins of these cell lines.
A difference in HpaII fragment hybridization intensity for a promoter between samples can occur due to methylation differences, differences in copy number, or due to restriction site polymorphisms. In cancer cell lines, relative to normal cell lines, there are fewer genes that showed an increased HpaII fragment hybridization, characteristic of copy number increases or hypomethylation (251 promoters), and conversely there are more genes with lower HpaII fragment hybridization, characteristic of copy number decreases or hypermethylation (286 promoters) (FIG. 8 ). An example of increased HpaII fragment hybridization (hypomethylation or copy number increase) in cancer lines is the promoter of CTAG1, which is over-expressed in some lung and thyroid cancers,51,52 although this overexpression has not been attributed to hypomethylation or copy number changes.
Methylation
We used 5-aza deoxycytidine (d5-AzaC) as a means of achieving global demethylation in order to determine if differences in hybridization could be partially reversed, indicating methylation as the underlying cause. For example when LNCAP cells are treated with d5-AzaC and the HpaII fragment profile compared to that for untreated cells, reductions in hybridization intensities are detected for hundreds of genes. As a group, the shift of these genes to a more demethylated status is highly significant (P 0.001). Methylation status was also examined by methylation-specific PCR for a group of 14 randomly selected genes. Eight out of 14 were hypermethylated in PC3M relative to 267B1 and one gene was hypermethylated in 267B1 all of which supported the array data. These events likely regulate transcription (FIG. 9 , see also below: Correlation between RNA Expression and HpaII Fragment Hybridization).
Detection of Copy Number Change
Of the remaining five genes that showed no changes or changes in the wrong direction, all were located on chromosome 5. When the HpaII-ligation-PCR data for three cell lines are plotted in the order of their occurrence in the genome, the best candidate chromosome regions for widespread methylation or aneuploidy are apparent (FIG. 9A-C) . This analysis suggests that the five genes that appeared to be differentially methylated, are, in fact, altered in copy number. Among the aneuploidy changes that are observed by hybridization to the promoter arrays and that have been reported previously are changes in chromosome 6 in LNCaP, chromosomes 8, 10, 14 in PC353 and many sporadic changes previously observed in prostate cancer. 54 The results reported by the array as indicating copy number changes are supported by the comparison of PC3M cells to immortal prostate epithelial 267B1 cells using MspI-ligation-PCR (FIG. 10D) . MspI is an enzyme which cuts at the same CCGG site as HpaII but which is insensitive to methylation at most sites. The normalized ratio (PC3M/267B1) is plotted against the chromosomal position of each promoter (FIG.10D ). This is a simple variation on the comparative genomic hybridization (CGH) method.55 The correspondence of the major features for chromosomes 5, 10, 12, 14 and 15 is consistent with the results based on the HpaII protocol. Among the 504 promoters with significant differences between prostate cancer and the normal cell line, eight genes are known as methylation-regulated genes in prostate cancer; CD44, CDKN1A, ESR1, PLAU, RARB, SFN, TNFRSF6, TSPY, and 13 more are known in other cancers; ARHI, BCL-2, BRCA1, CDKN2C, GADD45A, MTAP, PGR, SLC26A4, SPARC, SYK, TJP2, UCHL1, WIT-1 (for references see Wang et al. 20052) . Similarly, methylation of SFN and PLAU in LNCaP but not PC3 has been reported before56,57 which is consistent with the observations based on the promoter array analysis.
Other than dramatic differences in their growth properties and metastatic abilities58,59 one of the most striking differences between PC3M and LNCaP, is that the latter is almost unique among prostate cancer cell lines in still being androgen dependent. In this experiment, 29 genes showed loss of hybridization in HpaII fragment in LNCaP and 19 genes showed loss of hybridization in PC3M, indicating hypermethylation or copy number loss. We looked for differences in hybridization between PC3M and LNCaP among 261 known and suspected androgen-regulated genes present on the array.60 Among known or suspected androgen receptor-regulated genes that may be methylated or reduced in copy number in LNCaP relative to PC3M were GG2-1 (TNF-induced protein), GABARAPL2 (GABA(A) receptor-associated protein-like 2). In PC3M the list included FLJ13782 hypothetical protein, TSPY (testis-specific protein, Y-linked) and RPS4Y (ribosomal protein S4, Y-linked isoform). Expression from the Y chromosome has been of interest in prostate cancer61,62 and changes in methylation of EIF1AY, MGC26641, PRKY, RPS4Y, SHOX, TSPY, TSPYQ1 and VCY are observed in our experiments, whereas the few other Y chromosome genes on the array act as internal controls for this observation because they are seemingly not differentially methylated.
That an experiment involving three relatively normal prostate cell lines and five prostate cancer cell lines pointed to a large number of genes that were previously known to be differentially methylated in cancer, particularly prostate cancer, sup180 ports the observation that cell lines and primary tumors generally have similar overall distribution and frequencies of gene methylation63 and that prostate cancer cell lines may have the same "hypermethylation fingerprint" as primary and metastatic prostate cancers.64
Correlation between RNA Expression and HpaII Fragment Hybridization
The RNA expression levels of two cell lines, PC3M and 267B1, were obtained using Affymetrix U133A GeneChips. 51.653.5% genes were called as present for these samples. When methylation differences are plotted against gene expression differences between PC3M and 267B1 for all the genes that showed HpaII fragment hybridization differences and gene expression differences, there is a significant correlation (40 genes, r 0.68, P 0.001), FIGURE 9. The majority of genes that are differentially hybridized by amplified HpaII fragments in the study are not considered in this comparison because these genes happen not to be sufficiently expressed as judged by the Affymetrix criteria. Twenty-seven genes, including three genes with no apparent CpG island in the promoter region, are less hybridized by HpaII fragments (consistent with hypermethylation or copy number loss) in PC3M relative to 267B1. For these genes expression was also decreased in PC3M, as would be expected if methylation or copy number loss is associated with downregulation of expres- sion. There are nine genes, including two genes with no CpG island in promoter region, with increased hybridization of HpaII fragments (consistent with hypomethylation or copy number increase) in PC3M relative to 267B1 and gene expression of these genes is higher in PC3M, also as expected. There were only four genes where the prediction of methylation or copy number loss was associated with an increase in gene expression level. It will be of interest to explore these exceptions further. Finally, the ratios of PC3M expression data relative to 267B1 was plotted against chromosome position in FIGURE 10E. Perhaps surprisingly, there are readily detectable global effects of aneuploidy on averaged RNA expression along the chromosomes.
Summary
The comparisons of the immortalized prostate epithelial and cancer cells lines revealed a high degree of differential hybridization, 18.5% of all promoter sequences represented on the array. Most differences could be eliminated by first treating dividing cells with the methylation inhibitor d5-azaC. Moreover, promoter methylation generally correlated with reduced RNA expression. As for the studies of activated transcription factor DNA complexes, the number of promoters detected is considerably larger than anticipated based on the number of individual genes reported to be regulated by methylation in prostate cancer. Similar to the results observed for active transcription factor-DNA complexes, while many known or suspected methylation targets were observed, the vast majority of genes that appear to be both differentially methylated and differentially regulated between prostate epithelial and cancer cell lines are novel methylation targets, including PAK6, RAD50, TLX3, PIR51, MAP2K5, INSR, FBN1, GG2-1, representing a rich new source of candidate genes to study the role of DNA methylation in prostate tumors. The use of promoter arrays appears to be a promising new avenue for the investigation of coordinated gene regulation. The promoter array described here has been expanded to over 10 K unique promoter sequences using the primer set developed by the Whitehead Institute. We examined MCF7 cells with and without stable expression of HER2 termed MCF7PHER2 and MCF7pcDNA cells. MCF7HER2 cells stably over express HER2 to levels comparable to BT474, a human breast cancer cell line with known high levels of amplified and expressed HER2. In contrast, immuno-reactive HER2 was undetectable in the MCF7pcDNA control cells. In order to confirm that over-expressed HER2 was functional, we examined the level of phosphorylation of HER2 and known downstream HER2-activated targets, HER3, HOXA10 and NFκB . HER2 was observed to be constitutively phosphorylated in agreement with our previously published observations 30 31 {Mitra, 2009 #70 . In addition we observed increased phosphorylation of HER3 heterodimer partner of HER2 which was not observed in MCF7pcDNA cells as well as HoxA10 and NFκB . These results indicate that cells used here reliably exhibit expression and signal transduction features of HER2 signaling. Relative expression was determined using densitometry (Alpha Ease FC TM (Alpha Innotech Corporation) imager software). The average signal (sum of pixels/area) for the protein of interest was calculated and compared to the average signal detected for the housekeeping gene β-actin. There are relatively few genes with number > 3 and the probabilities for these cases were combined to form "average" probability per site as described in the Materials and Methods. The binding probabilities, p, decline as the binding number increases from 1 to 2 to 3 or more sites per gene indicating that the tightness of binding is correlated with increased number of sites for a given gene. The relationship between the probability of binding and the number of POL II sites/gene is independent of HER2 since a similar trend holds for the 678 significant POL II-bound genes of the MCF7 control cells with different gene identities. Genes with multiple binding sites also tend to cluster near the TSS (SI > 4) whereas genes with higher values tend to have few binding sites/gene which are found downstream (SI < 4). These results identify a class of looser bound more mobile genes located in the 3' coding region. Our results illustrate a large effect of HER2 overexpression in shifting the POL II binding site (accumulation) toward a more 3' coding region. Expression levels of ALDH1A1, NANOG, SOX2 and OCT3/4 was quantified using real time RT-PCR in attached culture of MCF7pcDNA, MCF7HER2 and BT474 as well as mammospheres of the same cells. GAPDH ( housekeeping gene) was used as an internal control. The relative expression was determined using 2 ΔΔCt method. The value represents the mean s.e. of the technical replicates. (*) the original expression level is 10 fold higher than shown here.
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